Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Selinexor · Xpovio, KPT-330

Small molecule · Inhibitor of exportin 1 (CRM1/XPO1) (XPO1) · developed by Karyopharm Theraps

Approved FDA, Jul 2019
KPTI Developer
9 Registered trials

What is Selinexor?

Selinexor is an oral nuclear export inhibitor that blocks exportin 1 (XPO1, also called CRM1), causing tumor suppressor proteins to accumulate in the nucleus and cancer cells to undergo cell cycle arrest and apoptosis. It is used in multiple myeloma and is studied in several leukemias, lymphoma, myelofibrosis, thrombocytopenia and sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Xpovio, KPT-330, KCP-330
Drug type
Small molecule
Targets
exportin 1 (CRM1/XPO1) (XPO1)
Mechanism
Inhibitor of exportin 1 (CRM1/XPO1) (XPO1)
Pathways
nuclear export of tumor suppressor proteins, c-myc and cyclin D1 reduction, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Karyopharm Theraps (KPTI)
FDA status
Approved as Xpovio (July 3, 2019), NDA212306 · FDA label
UNII
31TZ62FO8F

✅ FDA-approved uses

From the indications section of the FDA label (version of May 12, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05028348 Phase 3 Multiple Myeloma Active not recruiting KPTI
NCT04442022 Phase 2/3 Relapsed/Refractory Diffuse Large B-cell Lymphoma Active not recruiting KPTI
NCT05980806 Phase 2 Myelofibrosis Recruiting KPTI
NCT04717700 Phase 2 Multiple Myeloma Active not recruiting KPTI
NCT04661137 Phase 2 Multiple Myeloma Recruiting KPTI
NCT03732703 Phase 1/2 Relapsed Refractory Multiple Myeloma Completed KPTI
NCT03193437 Phase 2 Thymoma Terminated KPTI
NCT02091245 Phase 1 Relapsed Acute Lymphoblastic Leukemia (ALL) Active not recruiting KPTI
NCT01896505 Phase 1 Sarcoma Completed KPTI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Myelogenous Leukemia (CML) in Blast CrisisMild ThrombocytopeniaModerate ThrombocytopeniaMultiple MyelomaMyelofibrosisRefractory Acute Lymphoblastic Leukemia (ALL)Refractory Acute Myelogenous Leukemia (AML)Refractory Biphenotypic LeukemiaRefractory Mixed Lineage LeukemiaRelapsed Acute Lymphoblastic Leukemia (ALL)Relapsed Acute Myelogenous Leukemia (AML)Relapsed Biphenotypic LeukemiaRelapsed Mixed Lineage LeukemiaRelapsed/Refractory Diffuse Large B-cell Lymphoma

Other drugs acting on XPO1

More from Karyopharm Theraps

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KPTI page.

Follow KPTI, the company behind Selinexor

See KPTI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KPTI catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.